Zobrazeno 1 - 10
of 2 523
pro vyhledávání: '"Ponatinib"'
Publikováno v:
Heliyon, Vol 10, Iss 19, Pp e38637- (2024)
Ponatinib is a potent tyrosine kinase inhibitor that is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. To further expand its clinical applications, accurate quantification of
Externí odkaz:
https://doaj.org/article/cf48f828544f4649ac7a51d7e42bfd22
Autor:
Mario Manzanares, Fernando Ramos-Martín, Sara Rodríguez-Mora, Guiomar Casado-Fernández, Clara Sánchez-Menéndez, Alicia Simón-Rueda, Elena Mateos, Miguel Cervero, Adam M. Spivak, Vicente Planelles, Montserrat Torres, Valentín García-Gutiérrez, Mayte Coiras
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
HIV-1 infection cannot be cured due to long-lived viral reservoirs formed by latently infected CD4+ T cells. “Shock and Kill” strategy has been considered to eliminate the viral reservoir and achieve a functional cure but the stimulation of cytot
Externí odkaz:
https://doaj.org/article/9854eb1f037746858c873d3668929237
Autor:
Takayoshi Tachibana, Masatsugu Tanaka, Yuma Noguchi, Yuho Najima, Daichi Sadato, Yuka Harada, Yotaro Tamai, Noriko Doki, Hideaki Nakajima
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
The outcomes of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant to new drugs such as tyrosine kinase inhibitors, inotuzumab ozogamicin (InO) and blinatumomab are dismal. We treated two cases of Ph+ALL resista
Externí odkaz:
https://doaj.org/article/0209de57f1fb4edd864fcf22b274fc1b
Autor:
Waleeporn Kaewlert, Chadamas Sakonsinsiri, Worachart Lert-itthiporn, Panupong Mahalapbutr, Saba Ali, Thanyada Rungrotmongkol, Apinya Jusakul, Napat Armartmuntree, Chawalit Pairojkul, Guofei Feng, Ning Ma, Somchai Pinlaor, Mariko Murata, Raynoo Thanan
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 180, Iss , Pp 117569- (2024)
Cholangiocarcinoma (CCA) is an oxidative stress-driven liver cancer with bile duct epithelial cell phenotypes and currently lacks effective treatments, making targeted drug therapy urgently needed. Oxidative stress plays a critical role in CCA carcin
Externí odkaz:
https://doaj.org/article/3109d0f9d6ce45d78f33afebd09e291e
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 180, Iss , Pp 117503- (2024)
Background: Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) who are resistant to the therapies with
Externí odkaz:
https://doaj.org/article/757bb0282c0e4489ae08f5ef1af75a4b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ji Eun Shin, Soo-Hyun Kim, Mingyu Kong, Hwa-Ryeon Kim, Sungmin Yoon, Kyung-Mi Kee, Jung Ah Kim, Dong Hyeon Kim, So Yeon Park, Jae Hyung Park, Hongtae Kim, Kyoung Tai No, Han-Woong Lee, Heon Yung Gee, Seunghee Hong, Kun-Liang Guan, Jae-Seok Roe, Hyunbeom Lee, Dong-Wook Kim, Hyun Woo Park
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-21 (2023)
Abstract Background Although the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs) rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug resistance during blast phase (BP) progression remains a critical challeng
Externí odkaz:
https://doaj.org/article/8eab8b0fc14041c7aad65f5279559725
Publikováno v:
Hematology Reports, Vol 15, Iss 4, Pp 670-683 (2023)
In Philadelphia chromosome-positive B-cell (Ph+) acute lymphoblastic leukemia (LLA), growing evidence has accumulated regarding the efficacy of low-intensity and chemo-free regimens. Our objective was to analyze all recent trials evaluating these tre
Externí odkaz:
https://doaj.org/article/e4c8fbb9e9a8485a828999abc21d3b44
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 5, Pp 1071-1081 (2023)
Alternative protein-protein interactions (PPIs) arising from mutations or post-translational modifications (PTMs), termed phenotypic switching (PS), are critical for the transmission of alternative pathogenic signals and are particularly significant
Externí odkaz:
https://doaj.org/article/58885eceb29d48db9675441852f3e876
Autor:
Seiichi Okabe, Akihiko Gotoh
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Abelson (ABL) tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML); however, many patients develop resistance during ABL TKI therapy. Vitamin K2 (VK2) is a crucial fat-soluble vitamin used to acti
Externí odkaz:
https://doaj.org/article/9d444521026f451ba0a70499d722cdbc